Published on in Vol 11 (2025)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/65118, first published .
Treatment Outcomes From Erlotinib and Gefitinib in Advanced Epidermal Growth Factor Receptor–Mutated Nonsquamous Non–Small Cell Lung Cancer in Aotearoa New Zealand From 2010 to 2020: Nationwide Whole-of-Patient-Population Retrospective Cohort Study

Treatment Outcomes From Erlotinib and Gefitinib in Advanced Epidermal Growth Factor Receptor–Mutated Nonsquamous Non–Small Cell Lung Cancer in Aotearoa New Zealand From 2010 to 2020: Nationwide Whole-of-Patient-Population Retrospective Cohort Study

Treatment Outcomes From Erlotinib and Gefitinib in Advanced Epidermal Growth Factor Receptor–Mutated Nonsquamous Non–Small Cell Lung Cancer in Aotearoa New Zealand From 2010 to 2020: Nationwide Whole-of-Patient-Population Retrospective Cohort Study

Phyu Sin Aye   1 , PhD ;   Joanne Barnes   2 , PhD ;   George Laking   3 , PhD ;   Laird Cameron   4 , MBChB ;   Malcolm Anderson   5 , MBBS ;   Brendan Luey   6 , PhD ;   Stephen Delany   7 , MBChB ;   Dean Harris   8 , MBChB ;   Blair McLaren   9 , MBChB ;   Elliott Brenman   10 , BM, BS ;   Jayden Wong   11 , MBChB ;   Ross Lawrenson   12 , MBBS ;   Michael Arendse   13 , MMed ;   Sandar Tin Tin   14 , PhD ;   Mark Elwood   14 , DSc ;   Philip Hope   15 ;   Mark James McKeage   1 , PhD

1 Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand

2 School of Pharmacy, University of Auckland, Auckland, New Zealand

3 Te Aka Mātauranga Matepukupuku Centre for Cancer Research, University of Auckland, Auckland, New Zealand

4 Department of Medical Oncology, Te Pūriri o Te Ora Regional Cancer and Blood Service, Te Whatu Ora Health New Zealand, Auckland City Hospital, Auckland, New Zealand

5 Department of Medical Oncology, Te Whatu Ora Health New Zealand Te Pae Hauuora o Ruahine o Tararua, Palmerston North Hospital, Palmerston North, New Zealand

6 Wellington Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital, Coast and Hutt Valley, Wellington Hospital, Wellington, New Zealand

7 Department of Oncology, Te Whatu Ora Health New Zealand Nelson Marlborough, Nelson Hospital, Nelson, New Zealand

8 Oncology Service, Te Whatu Ora—Waitaha Canterbury, Christchurch Hospital, Christchurch, New Zealand

9 Southern Blood and Cancer Service, Te Whatu Ora Southern, Dunedin Hospital, Dunedin, New Zealand

10 Cancer and Haematology Services, Te Whatu Ora Health New Zealand Haora a Toi Bay of Plenty, Tauranga Hospital, Tauranga, New Zealand

11 Cancer Services, Te Whatu Ora Health New Zealand Waikato, Waikato Hospital, Hamilton, New Zealand

12 Medical Research Centre, University of Waikato, Hamilton, New Zealand

13 Department of Pathology, Te Whatu Ora Health New Zealand Waikato, Waikato Hospital, Hamilton, New Zealand

14 Department of Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand

15 Lung Foundation New Zealand, Auckland, New Zealand

Corresponding Author:

  • Phyu Sin Aye, PhD
  • Department of Pharmacology and Clinical Pharmacology
  • University of Auckland
  • 85 Park Road
  • Auckland, 1023
  • New Zealand
  • Phone: 64 9 373 7999
  • Email: p.aye@auckland.ac.nz